Spero Therapeutics Inc has a consensus price target of $3.67, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 18, 2024, November 14, 2023, and September 5, 2023. With an average price target of $7 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 311.60% upside for Spero Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/18/2024 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 311.6% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
11/14/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 311.6% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
09/05/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 311.6% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
08/14/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 311.6% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $7 | Maintains | Buy | Get Alert |
08/01/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 252.8% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
07/20/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 252.8% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
04/10/2023 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 252.8% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | → Buy | Get Alert |
09/26/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 252.8% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $6 | Maintains | Buy | Get Alert |
09/23/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 370.39% | Evercore ISI Group | Josh Schimmer | $2 → $8 | Upgrade | In-Line → Outperform | Get Alert |
08/15/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 311.6% | HC Wainwright & Co. | Raghuram Selvaraju | $10 → $7 | Maintains | Buy | Get Alert |
05/23/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 487.99% | HC Wainwright & Co. | Raghuram Selvaraju | $37 → $10 | Maintains | Buy | Get Alert |
05/20/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 17.6% | Berenberg | Esther Hong | → $2 | Downgrade | Buy → Hold | Get Alert |
05/17/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 194% | Cantor Fitzgerald | Louise Chen | $27 → $5 | Maintains | Overweight | Get Alert |
05/04/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | — | Cowen & Co. | Ritu Baral | — | Downgrade | Outperform → Market Perform | Get Alert |
05/04/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 17.6% | Evercore ISI Group | Josh Schimmer | $40 → $2 | Downgrade | Outperform → In-Line | Get Alert |
04/18/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 2075.57% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $37 | Maintains | Buy | Get Alert |
03/21/2022 | SPRO | Buy Now | Spero Therapeutics | $1.70 | 2428.37% | HC Wainwright & Co. | Raghuram Selvaraju | $40 → $43 | Maintains | Buy | Get Alert |
10/01/2021 | SPRO | Buy Now | Spero Therapeutics | $1.70 | — | Oppenheimer | Kevin DeGeeter | — | Downgrade | Outperform → Perform | Get Alert |
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on March 18, 2024. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 311.60% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics reiterated their buy rating.
The last upgrade for Spero Therapeutics Inc happened on September 23, 2022 when Evercore ISI Group raised their price target to $8. Evercore ISI Group previously had an in-line for Spero Therapeutics Inc.
The last downgrade for Spero Therapeutics Inc happened on May 20, 2022 when Berenberg changed their price target from N/A to $2 for Spero Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a reiterated with a price target of $0.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.70, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.